Lilly breaks the bank on the potential for RNA with $700M investment in Boston's Seaport
In the latest boom across drug R&D, Big Pharma has dumped billions into research for RNA-based therapies, betting big on the future in that space. Now, Eli Lilly wants an even bigger piece of the action and will plant its flag in Boston to help pave the way.
Lilly will dole out $700 million for a new research site at Boston’s Seaport district as part of the company’s broader push into RNA medicines, the Indianapolis-based drugmaker said Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.